Roderick Skinner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2951537/publications.pdf

Version: 2024-02-01

66343 79698 6,310 143 42 73 citations h-index g-index papers 144 144 144 6312 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Inconsistencies in fertility preservation for young people with cancer in the UK. Archives of Disease in Childhood, 2022, 107, 265-270.	1.9	4
2	Impact of era of diagnosis on causeâ€specific late mortality among 77 423 fiveâ€year European survivors of childhood and adolescent cancer: The <scp>PanCareSurFup</scp> consortium. International Journal of Cancer, 2022, 150, 406-419.	5.1	11
3	Social inequalities in treatment receipt for childhood cancers in Ireland: A populationâ€based analysis. International Journal of Cancer, 2022, 150, 941-951.	5.1	3
4	The PanCareFollowUp Care Intervention: A European harmonised approach to person-centred guideline-based survivorship care after childhood, adolescent and young adult cancer. European Journal of Cancer, 2022, 162, 34-44.	2.8	17
5	Childhood cancer survivorship care during the COVID-19 pandemic: an international report of practice implications and provider concerns. Journal of Cancer Survivorship, 2022, 16, 1390-1400.	2.9	9
6	Childhood cancer survivors' perceptions of the barriers and facilitators to physical activity: a systematic review and thematic synthesis of qualitative evidence using the Theoretical Domains Framework. Health Psychology Review, 2022, , 1-36.	8.6	9
7	Male breast cancer after childhood cancer: Systematic review and analyses in the PanCareSurFup cohort. European Journal of Cancer, 2022, 165, 27-47.	2.8	6
8	Recommendations for the surveillance of mental health problems in childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, The, 2022, 23, e184-e196.	10.7	25
9	Hypothalamic-Pituitary and Other Endocrine Surveillance Among Childhood Cancer Survivors. Endocrine Reviews, 2022, 43, 794-823.	20.1	20
10	Recommendations for the surveillance of education and employment outcomes in survivors of childhood, adolescent, and young adult cancer: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Cancer, 2022, 128, 2405-2419.	4.1	29
11	Epigenetic regulator genes direct lineage switching inÂ <i>MLL/AF4</i> leukemia. Blood, 2022, 140, 1875-1890.	1.4	26
12	HSCT is effective in patients with PSTPIP1-associated myeloid-related proteinemia inflammatory (PAMI) syndrome. Journal of Allergy and Clinical Immunology, 2021, 148, 250-255.e1.	2.9	18
13	Counseling and surveillance of obstetrical risks for female childhood, adolescent, and young adultÂcancerÂsurvivors: recommendations fromÂtheÂlnternationalÂLate Effects of Childhood CancerÂGuidelineÂHarmonization Group. American Journal of Obstetrics and Gynecology, 2021, 224, 3-15.	1.3	35
14	Risk of cerebrovascular disease among 13 457 fiveâ€year survivors of childhood cancer: A populationâ€based cohort study. International Journal of Cancer, 2021, 148, 572-583.	5.1	15
15	Identifying and exploring the self-management strategies used by childhood cancer survivors. Journal of Cancer Survivorship, 2021, 15, 344-357.	2.9	8
16	Increased risk of cardiac ischaemia in a pan-European cohort of 36 205 childhood cancer survivors: a PanCareSurFup study. Heart, 2021, 107, 33-41.	2.9	11
17	The Concept of Cancer Survivorship and Models for Long-Term Follow-Up. Frontiers of Hormone Research, 2021, 54, 1-15.	1.0	9
18	Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, The, 2021, 22, e68-e80.	10.7	37

#	Article	IF	CITATIONS
19	Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, The, 2021, 22, e57-e67.	10.7	95
20	Excellent overall and chronic graftâ€ <i>versus</i> à€hostâ€diseaseâ€free eventâ€free survival in Fanconi anaemia patients undergoing matched related―and unrelatedâ€donor bone marrow transplantation using alemtuzumab–Flu–Cy: the UK experience. British Journal of Haematology, 2021, 193, 804-813.	2 . 5	10
21	Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, The, 2021, 22, e196-e206.	10.7	24
22	The European multistakeholder PanCareFollowUp project: novel, person-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for cancer survivors and caregivers. European Journal of Cancer, 2021, 153, 74-85.	2.8	18
23	Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Diabetes and Endocrinology,the, 2021, 9, 622-637.	11.4	29
24	European PanCareFollowUp Recommendations for surveillance of late effects of childhood, adolescent, and young adult cancer. European Journal of Cancer, 2021, 154, 316-328.	2.8	38
25	Coronary artery disease surveillance among childhood, adolescentÂand young adult cancer survivors: A systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. European Journal of Cancer, 2021, 156, 127-137.	2.8	26
26	Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group. Cancer Treatment Reviews, 2021, 100, 102296.	7.7	16
27	Editorial: Adverse and Toxic Effects of Childhood Cancer Treatments. Frontiers in Oncology, 2021, 11, 795664.	2.8	4
28	Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. Lancet Haematology,the, 2020, 7, e50-e60.	4.6	53
29	Guidance regarding COVIDâ€19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatric Blood and Cancer, 2020, 67, e28702.	1.5	25
30	Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group. Journal of Clinical Oncology, 2020, 38, 4194-4207.	1.6	55
31	The development of health behaviour change interventions for childhood cancer survivors: The need for a behavioural science approach. Pediatric Blood and Cancer, 2020, 67, e28500.	1.5	10
32	Large variation in assessment and outcome definitions to describe the burden of longâ€term morbidity in childhood cancer survivors: A systematic review. Pediatric Blood and Cancer, 2020, 67, e28611.	1.5	4
33	Recommendations for the surveillance of cancer-related fatigue in childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Journal of Cancer Survivorship, 2020, 14, 923-938.	2.9	48
34	Risk of digestive cancers in a cohort of 69 460 five-year survivors of childhood cancer in Europe: the PanCareSurFup study. Gut, 2020, , gutjnl-2020-322237.	12.1	5
35	The Critical Role of Clinical Practice Guidelines and Indicators in High-Quality Survivorship After Childhood Cancer. Pediatric Clinics of North America, 2020, 67, 1069-1081.	1.8	5
36	New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT. Blood Advances, 2020, 4, 2418-2429.	5 . 2	24

#	Article	IF	CITATIONS
37	Variations in screening and management practices for subsequent asymptomatic meningiomas in childhood, adolescent and young adult cancer survivors. Journal of Neuro-Oncology, 2020, 147, 417-425.	2.9	8
38	Renal and Hepatic Health After Childhood Cancer. Pediatric Clinics of North America, 2020, 67, 1203-1217.	1.8	5
39	PEPtalk2: results of a pilot randomised controlled trial to compare VZIG and aciclovir as postexposure prophylaxis (PEP) against chickenpox in children with cancer. Archives of Disease in Childhood, 2019, 104, 25-29.	1.9	11
40	Evidence-based recommendations for the organization of long-term follow-up care for childhood and adolescent cancer survivors: a report from the PanCareSurFup Guidelines Working Group. Journal of Cancer Survivorship, 2019, 13, 759-772.	2.9	60
41	Optimizing Detection of Low Bone Mineral Density in Childhood Cancer Survivors. Journal of Clinical Oncology, 2019, 37, 2193-2195.	1.6	2
42	Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup. European Journal of Cancer, 2019, 117, 71-83.	2.8	12
43	Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet Oncology, The, 2019, 20, e29-e41.	10.7	90
44	Non-posttransplant lymphoproliferative disorder malignancy after hematopoietic stem cell transplantation in patients with primary immunodeficiency: UK experience. Journal of Allergy and Clinical Immunology, 2018, 141, 2319-2321.e1.	2.9	7
45	Risk of Subsequent Bone Cancers Among 69 460 Five-Year Survivors of Childhood and Adolescent Cancer in Europe. Journal of the National Cancer Institute, 2018, 110, 183-194.	6.3	38
46	High transplant-related mortality associated with haematopoietic stem cell transplantation for paediatric therapy-related acute myeloid leukaemia (t-AML). A study on behalf of the United Kingdom Paediatric Blood and Bone Marrow Transplant Group. Bone Marrow Transplantation, 2018, 53, 1165-1169.	2.4	6
47	Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance. Pediatric Nephrology, 2018, 33, 215-225.	1.7	53
48	T-cell receptor αβ+ and CD19+ cell–depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency. Journal of Allergy and Clinical Immunology, 2018, 141, 1417-1426.e1.	2.9	119
49	Surveillance for Late Effects in Childhood Cancer Survivors. Journal of Clinical Oncology, 2018, 36, 2216-2222.	1.6	134
50	Models of Care for Survivors of Childhood Cancer From Across the Globe: Advancing Survivorship Care in the Next Decade. Journal of Clinical Oncology, 2018, 36, 2223-2230.	1.6	65
51	Improving Male Reproductive Health After Childhood, Adolescent, and Young Adult Cancer: Progress and Future Directions for Survivorship Research. Journal of Clinical Oncology, 2018, 36, 2160-2168.	1.6	48
52	The PanCareSurFup consortium: research and guidelines to improve lives for survivors of childhood cancer. European Journal of Cancer, 2018, 103, 238-248.	2.8	30
53	Risk of Soft-Tissue Sarcoma Among 69 460 Five-Year Survivors of Childhood Cancer in Europe. Journal of the National Cancer Institute, 2018, 110, 649-660.	6.3	36
54	Long-term survivors of childhood cancer: cure and careâ€"the Erice Statement (2006) revised after 10Âyears (2016). Journal of Cancer Survivorship, 2018, 12, 647-650.	2.9	21

#	Article	IF	CITATIONS
55	The â€~Survivorship Passport' for childhood cancer survivors. European Journal of Cancer, 2018, 102, 69-81.	2.8	67
56	Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. Lancet Oncology, The, 2017, 18, e75-e90.	10.7	158
57	Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes. Bone Marrow Transplantation, 2017, 52, 775-777.	2.4	16
58	Pregnancy and Labor Complications in Female Survivors of Childhood Cancer: The British Childhood Cancer Survivor Study. Journal of the National Cancer Institute, 2017, 109, .	6.3	51
59	Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT. Biology of Blood and Marrow Transplantation. 2017. 23. 1422-1428.	2.0	43
60	Reply: Methotrexate neurotoxicity due to drug interactions: an inadequate folinic acid effect. Cancer Chemotherapy and Pharmacology, 2017, 79, 841-842.	2.3	2
61	Accuracy of cystatin C for the detection of abnormal renal function in children undergoing chemotherapy for malignancy: a systematic review using individual patient data. Supportive Care in Cancer, 2017, 26, 1635-1644.	2.2	7
62	Young adult survivors of childhood acute lymphoblastic leukemia show evidence of chronic inflammation and cellular aging. Cancer, 2017, 123, 4207-4214.	4.1	66
63	The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. Biology of Blood and Marrow Transplantation, 2017, 23,	2.0	33
64	An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients. Ecancermedicalscience, 2016, 10, 608.	1.1	5
65	A School Passport as Part of a Protocol to Assist Educational Reintegration After Medulloblastoma Treatment in Childhood. Pediatric Blood and Cancer, 2016, 63, 1636-1642.	1.5	11
66	The long-term psychosocial impact of cancer: the views of young adult survivors of childhood cancer. European Journal of Cancer Care, 2016, 25, 428-439.	1.5	29
67	Transition guidelines: An important step in the future care for childhood cancer survivors. A comprehensive definition as groundwork. European Journal of Cancer, 2016, 54, 64-68.	2.8	44
68	The role of the RAS pathway in iAMP21-ALL. Leukemia, 2016, 30, 1824-1831.	7.2	38
69	Health promotion and information provision during long-term follow-up for childhood cancer survivors: A service evaluation. Pediatric Hematology and Oncology, 2016, 33, 359-370.	0.8	4
70	Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients. Cancer Chemotherapy and Pharmacology, 2016, 78, 1093-1096.	2.3	26
71	European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies. Pediatric Blood and Cancer, 2016, 63, 139-148.	1.5	45
72	<scp>BCSH</scp> / <scp>BSBMT</scp> / <scp>UK</scp> clinical virology network guideline: diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation. British Journal of Haematology, 2016, 173, 380-393.	2.5	40

#	Article	IF	CITATIONS
73	Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium. Journal of Clinical Oncology, 2016, 34, 3440-3450.	1.6	173
74	Long term cause specific mortality among 34 489 five year survivors of childhood cancer in Great Britain: population based cohort study. BMJ, The, 2016, 354, i4351.	6.0	95
75	Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncology, The, 2016, 17, e231-e239.	10.7	194
76	Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters. Bone Marrow Transplantation, 2016, 51, 1482-1489.	2.4	28
77	Accelerated Aging in Bone Marrow Transplant Survivors. JAMA Oncology, 2016, 2, 1267-1268.	7.1	4
78	â€~Acceptability' of a new oral suspension formulation of mercaptopurine in children with acute lymphoblastic leukaemia. Journal of Oncology Pharmacy Practice, 2016, 22, 387-395.	0.9	14
79	Haploidentical CD3 TCRÎ \pm Î 2 and CD19-depleted second stem cell transplant for steroid-resistant acute skin graft versus host disease. Journal of Allergy and Clinical Immunology, 2016, 138, 603-605.e1.	2.9	4
80	Late Cardiac Events after Childhood Cancer: Methodological Aspects of the Pan-European Study PanCareSurFup. PLoS ONE, 2016, 11, e0162778.	2.5	11
81	Similar outcome of upfrontâ€unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the ⟨scp⟩UK⟨/scp⟩ Paediatric ⟨scp⟩BMT⟨/scp⟩ Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of ⟨scp⟩EBMT⟨/scp⟩. British Journal of Haematology. 2015. 171. 585-594.	2.5	146
82	Survivorship after childhood cancer: PanCare: A European Network to promote optimal long-term care. European Journal of Cancer, 2015, 51, 1203-1211.	2.8	98
83	Single amino acid charge switch defines clinically distinct proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1)–associated inflammatory diseases. Journal of Allergy and Clinical Immunology, 2015, 136, 1337-1345.	2.9	103
84	Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, The, 2015, 16, e123-e136.	10.7	453
85	Secondary Malignant Neoplasms Following Haematopoietic Stem Cell Transplantation in Childhood. Children, 2015, 2, 146-173.	1.5	11
86	The views of European clinicians on guidelines for longâ€term followâ€up of childhood cancer survivors. Pediatric Blood and Cancer, 2015, 62, 322-328.	1.5	32
87	Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia. Annals of Hematology, 2015, 94, 297-306.	1.8	38
88	Childhood cancer survivor cohorts in Europe. Acta Oncol \tilde{A}^3 gica, 2015, 54, 655-668.	1.8	97
89	The European Experience of Establishing Guidelines for Surveillance of the Childhood Cancer Survivor., 2015,, 25-35.		4
90	Recent advances in the management of graft-versus-host disease. Archives of Disease in Childhood, 2014, 99, 1150-1157.	1.9	27

#	Article	IF	Citations
91	Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, The, 2013, 14, e621-e629.	10.7	162
92	Renal and Pulmonary Late Effects of Cancer Therapy. Seminars in Oncology, 2013, 40, 757-773.	2.2	27
93	Developing a national †low risk' febrile neutropenia framework for use in children and young people's cancer care. Supportive Care in Cancer, 2013, 21, 1241-1251.	2.2	16
94	Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients (NICE Clinical) Tj ETQc	0 0 0 rgB1	7/Overlock 1
95	A reaudit of current febrile neutropenia practice in UK paediatric oncology centres prior to implementation of NICE guidance. Archives of Disease in Childhood, 2013, 98, 315-316.	1.9	15
96	Views of Childhood Cancer Survivors and Their Families on the Provision and Format of a Treatment Summary. Journal of Pediatric Hematology/Oncology, 2013, 35, 193-196.	0.6	5
97	Developing international consensus for late effects screening and guidance. Current Opinion in Supportive and Palliative Care, 2013, 7, 303-308.	1.3	11
98	Health problems in survivors of childhood cancer: the need for international collaboration in long-term follow-up care. Future Oncology, 2013, 9, 1667-1670.	2.4	6
99	A worldwide collaboration to harmonize guidelines for the longâ€term followâ€up of childhood and young adult cancer survivors: A report from the international late effects of Childhood Cancer Guideline Harmonization Group. Pediatric Blood and Cancer, 2013, 60, 543-549.	1.5	275
100	Treating childhood acute lymphoblastic leukemia in Malawi. Haematologica, 2013, 98, e1-e3.	3.5	9
101	Varicella postexposure prophylaxis in children with cancer: urgent need for a randomised controlled trial. Archives of Disease in Childhood, 2012, 97, 853.2-854.	1.9	4
102	Evaluation of Infection Control Advice for Patients at Risk of Chemotherapy-Induced Neutropenia in 2 Pediatric Oncology Centers: Cape Town, South Africa, and Newcastle-Upon-Tyne, UK. Pediatric Hematology and Oncology, 2012, 29, 73-84.	0.8	4
103	National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: The Need for Pediatric-Specific Long-Term Follow-up Guidelines. Biology of Blood and Marrow Transplantation, 2012, 18, 334-347.	2.0	82
104	Long-term effects of cancer therapy in children – functional effects, late mortality and long-term follow-up. Paediatrics and Child Health (United Kingdom), 2012, 22, 248-252.	0.4	6
105	Long-term effects of cancer therapy in children – organs, systems and tissues. Paediatrics and Child Health (United Kingdom), 2012, 22, 201-206.	0.4	5
106	Central nervous system lesions in Malawian children: identifying the treatable. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2012, 106, 567-569.	1.8	4
107	Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience. British Journal of Haematology, 2012, 157, 339-346.	2.5	105
108	Follow-Up Programs for Childhood Cancer Survivors in Europe: A Questionnaire Survey. PLoS ONE, 2012, 7, e53201.	2.5	47

#	Article	IF	Citations
109	Nephrotoxicity—What Do We Know and What Don't We Know?. Journal of Pediatric Hematology/Oncology, 2011, 33, 128-134.	0.6	51
110	Clinical outcomes and health-related quality of life (HRQOL) following haemopoietic stem cell transplantation (HSCT) for paediatric leukaemia. Child: Care, Health and Development, 2011, 37, 571-580.	1.7	24
111	PEPtalk: postexposure prophylaxis against varicella in children with cancer. Archives of Disease in Childhood, 2011, 96, 841-845.	1.9	18
112	Nephrotoxicity of cancer treatment in children. Pediatric Health, 2010, 4, 519-538.	0.3	12
113	Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose. Pediatric Blood and Cancer, 2010, 54, 983-989.	1.5	49
114	Healthâ€related quality of life and financial impact of caring for a child with Thalassaemia Major in the UK. Child: Care, Health and Development, 2010, 36, 118-122.	1.7	37
115	Influenza vaccination during cancer therapy. Archives of Disease in Childhood, 2010, 95, 569-570.	1.9	3
116	Long-term Cause-Specific Mortality Among Survivors of Childhood Cancer. JAMA - Journal of the American Medical Association, 2010, 304, 172.	7.4	375
117	INVASIVE ASPERGILLOSIS OF THE SMALL BOWEL IN AN INFANT WITH ACUTE MYELOID LEUKEMIA AND INTESTINAL OBSTRUCTION. Pediatric Hematology and Oncology, 2009, 26, 84-91.	0.8	5
118	Epidemiology of leukaemia and lymphoma in children and young adults from the north of England, 1990–2002. European Journal of Cancer, 2009, 45, 420-427.	2.8	23
119	Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors. European Journal of Cancer, 2009, 45, 3213-3219.	2.8	101
120	Challenges in the Management of Paediatric Febrile Neutropenia. Current Pediatric Reviews, 2009, 5, 229-233.	0.8	0
121	Donor lymphocyte infusions for post-transplant relapse of refractory anemia with excess blasts and monosomy 7. Pediatric Blood and Cancer, 2008, 50, 670-672.	1.5	6
122	Prevention and management of central venous catheter occlusion and thrombosis in children with cancer. Pediatric Blood and Cancer, 2008, 50, 826-830.	1.5	21
123	Prevention of varicella in children with cancer: Is it time to reconsider our strategy?. Pediatric Blood and Cancer, 2008, 51, 451-452.	1.5	0
124	Health-related quality of life in survivors of BMT for paediatric malignancy: a systematic review of the literature. Bone Marrow Transplantation, 2008, 42, 73-82.	2.4	70
125	Molecular diagnosis of vascular access device-associated infection in children being treated for cancer or leukaemia. Clinical Microbiology and Infection, 2008, 14, 213-220.	6.0	16
126	Vascular access for daunorubicin during childhood acute lymphoblastic leukaemia induction treatment: A UKCCSG supportive care group and MRC childhood leukaemia working party survey. European Journal of Oncology Nursing, 2008, 12, 476-478.	2.1	3

#	Article	IF	Citations
127	Long-term follow-up of children treated for cancer: why is it necessary, by whom, where and how?. Archives of Disease in Childhood, 2007, 92, 257-260.	1.9	7 5
128	Variation in policies for the management of febrile neutropenia in United Kingdom Children's Cancer Study Group centres. Archives of Disease in Childhood, 2007, 92, 495-498.	1.9	57
129	Should paediatric central lines be aspirated before use?. Archives of Disease in Childhood, 2007, 92, 517-518.	1.9	6
130	Long-term follow-up of people who have survived cancer during childhood. Lancet Oncology, The, 2006, 7, 489-498.	10.7	148
131	Preventing platinum-induced ototoxicity in children-is there a potential role for sodium thiosulfate?. Pediatric Blood and Cancer, 2006, 47, 120-122.	1.5	9
132	Novel mutations in a child with congenital amegakaryocytic thrombocytopenia. British Journal of Haematology, 2006, 135, 742-743.	2.5	15
133	Best practice in assessing ototoxicity in children with cancer. European Journal of Cancer, 2004, 40, 2352-2354.	2.8	50
134	Chronic ifosfamide nephrotoxicity in children. Medical and Pediatric Oncology, 2003, 41, 190-197.	1.0	127
135	Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment. Bone Marrow Transplantation, 2003, 31, 591-597.	2.4	21
136	Nephrotoxicity in survivors of Wilms' tumours in the North of England. British Journal of Cancer, 2002, 87, 1092-1098.	6.4	49
137	Plasma coenzyme Q10 in children and adolescents undergoing doxorubicin therapy. Clinica Chimica Acta, 2000, 302, 1-9.	1.1	22
138	True. British Journal of Cancer, 2000, 82, 1636-1645.	6.4	146
139	T-CELL FREQUENCY ANALYSIS DOES NOT PREDICT THE INCIDENCE OF GRAFT-VERSUS-HOST DISEASE IN HLA-MATCHED SIBLING BONE MARROW TRANSPLANTATION1. Transplantation, 2000, 70, 488-493.	1.0	20
140	Acute changes in urine protein excretion may predict chronic ifosfamide nephrotoxicity: a preliminary observation. Cancer Chemotherapy and Pharmacology, 1998, 41, 413-416.	2.3	10
141	Risk factors for ifosfamide nephrotoxicity in children. Lancet, The, 1996, 348, 578-580.	13.7	102
142	Strategies to prevent nephrotoxicity of anticancer drugs. Current Opinion in Oncology, 1995, 7, 310-315.	2.4	30
143	Assessment of chemotherapy-associated nephrotoxicity in children with cancer. Cancer Chemotherapy and Pharmacology, 1991, 28, 81-92.	2.3	62